




## KBT för ätstörningar

Vanligt förekommande behandling för ätstörningar i Sverige med olika kvalitet:  
Aktuell nationell och internationell läge

© Ala Ghaderi

1



## Behandling


Socialstyrelsen arbetar nu med nationella riktlinjer för Sverige

Vad föreslår andra nationella riktlinjer

- NICE
- APA
- Australien

© Ala Ghaderi

2



## För behandling av barn och ungdomar (NICE)


Familjebaserad behandling: FBT ("Maudsley" modellen):  
Förstahandsval!

Kognitiv beteendeterapi (I andra hand)

- När FBT inte passar eller önskas
- FBT inte ger effekt
- För äldre tonåringar

© Ala Ghaderi

3



## För vuxna med ätstörningar (NICE)

Vid bulimia nervosa, hetsättningsstörning och liknande:


- Kognitiv beteendeterapi (Förstahandsval)
- Interpersonell psykoterapi (Andrahandsval)

Vid anorexia nervosa:

- Ingen behandling är överlägsen annan
- KBT, MANTRA, SSCM tycks vara likvärdiga.
- Övriga alternativ har ännu mindre evidens.

© Ala Ghaderi

4




## ARFID?

KBT-baserad manual  
FBT-baserad manual  
Forskning pågår!

© Ala Ghaderi

5




## KBT och samhället

- Hjälsökande är ett första viktiga steg
- Majoriteten av patienterna med ätstörningar söker inte hjälp (40-80%)
- Vår studie från Sverige (n=3000) visar på skam, stigma och andra hinder:

Wanting to solve my own problems	55
Not wanting to lose control over my eating or weight	53
Feeling embarrassed about my problems	63
Feeling that my problems are not serious enough to warrant treatment	68
Feeling ashamed of my problems	59
Not knowing that my symptoms require professional help	51

© Ala Ghaderi

6




## Många söker inte hjälp! Bättre utredning?

- Ja!
- Fråga om ätvanor, sex, sömn, motion, umgänge...
- Använd en kort screeningsinstrument (SCOFF är ett alternativ)
- Vid tydligare misstanke: Använd EDE-Q och sedan intervju!

© Ala Chohan

7



## Aktuell forskning, trender, fynd...

8

## Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa

Laramie Duncan, Ph.D., Zeynep Yilmaz, Ph.D., Helena Gaspar, Ph.D., Raymond Walters, Ph.D., Jackie Goldstein, Ph.D., Veneri Anttila, Ph.D., Brendan Bulik-Sullivan, Ph.D., Stephan Ripke, M.D., Ph.D., Eating Disorders Working Group of the Psychiatric Genomics Consortium, Laura Thornton, Ph.D., Anke Hinney, Ph.D., Mark Daly, Ph.D., Patrick F. Sullivan, M.D., F.R.A.N.Z.C.P., Eleftheria Zeggini, Ph.D., Gerome Breen, Ph.D., Cynthia M. Bulik, Ph.D.

**Objective:** The authors conducted a genome-wide association study of anorexia nervosa and calculated genetic correlations with a series of psychiatric, educational, and metabolic phenotypes.

**Method:** Following uniform quality control and imputation procedures using the 1000 Genomes Project (phase 3) in 12 case-control cohorts comprising 3,495 anorexia nervosa cases and 10,982 controls, the authors performed standard association analysis followed by a meta-analysis across cohorts. Linkage disequilibrium score regression was used to calculate genome-wide common variant heritability (single-nucleotide polymorphism [SNP]-based heritability  $h^2_{SNP}$ ), partitioned heritability, and genetic correlations ( $r_g$ ) between anorexia nervosa and 159 other phenotypes.

**Results:** Results were obtained for 10,641,224 SNPs and insertion-deletion variants with minor allele frequencies >1% and imputation quality scores >0.6. The  $h^2_{SNP}$  of anorexia nervosa was 0.20 (SE=0.02), suggesting that a substantial fraction of the twin-based heritability arises from common genetic variation. The authors identified one genome-wide significant locus on chromosome 12 (rs4622308) in a region harboring a previously reported type 1 diabetes and autoimmune disorder locus. Significant positive genetic correlations were observed between anorexia nervosa and schizophrenia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant negative genetic correlations were observed between anorexia nervosa and body mass index, insulin, glucose, and lipid phenotypes.


**Conclusions:** Anorexia nervosa is a complex heritable phenotype for which this study has uncovered the first genome-wide significant locus. Anorexia nervosa also has large and significant genetic correlations with both psychiatric phenotypes and metabolic traits. The study results encourage a reconceptualization of this frequently lethal disorder as one with both psychiatric and metabolic etiology.

*Am J Psychiatry* 2017; 174:850–858. doi: 10.1176/appi.app.2017.162.1402

9



10




## Genetisk sårbarhet (2)


Kopplingar till typ-2 diabetes & autoimmuna sjukdomar  
Genetiskt positiva samband med schizofreni, neuroticism, antal år utbildning, och HDL  
Genetiskt negativa samband med BMI, insulin, glukos och lipid fenotyper (motsatsen till fetma)

© Ala Chohan

11




12

 **Karolinska Institutet**

## Anorexia nervosa och tvångssyndrom

Hög genetik korrelation mellan AN och OCD  
 Ingen signifikant individuell locus dock!  
 Positiva samband mellan "cross-disorder" fenotyp och andra psykiatriska störningar (bipolär & neuroticism)  
 Relationen mellan AN och metaboliska egenskaper var starkare än mellan OCD och metabolism  
**Mekanismer:**  
 > Utforskade samband mellan gemensam genetik risk för AN & OCD genuttryck för specifika vävnader och celltyper...


13

 **Karolinska Institutet**

## Genetik och igångsättningsålder vid AN?

Watson et al (2022). *Biological Psychiatry Global Open Science*, 2(4), 368-378

Tidig respektive normal igångsättningsålder visade signifikant distinkta genetiska korrelationsmönster med möjliga riskfaktorer för AN



14

 **Karolinska Institutet**

## DBT för ätstörningar ur DBT förespråkares perspektiv

- Tre varianter av DBT för ätstörningar:
- Stanford modellen (Debra Safer)
- Multidiagnostisk ED-DBT (mycket intensiv DBT)
- RO-DBT

Review och uppdatering:  
 > BenPorath et al. (2020). *Eating Disorders*, 28(2):101-121.doi: 10.1080/10640266.2020.1723371

15

 **Karolinska Institutet**

Journal of Behavior Therapy and Experimental Psychiatry 71 (2021) 101637  
 Contents lists available at ScienceDirect  
**Journal of Behavior Therapy and Experimental Psychiatry**  
 Journal homepage: [www.elsevier.com/locate/jbtep](http://www.elsevier.com/locate/jbtep)

### Radically open dialectical behavior therapy for anorexia nervosa: A multiple baseline single-case experimental design study across 13 cases<sup>a</sup>

Martina Isaksson<sup>a,\*</sup>, Ata Ghaderi<sup>b,1</sup>, Mia Ranklin<sup>a</sup>, Martina Wolf-Areholm<sup>a,2</sup>

<sup>a</sup> Department of Neuroscience, Psychiatry, Uppsala University, Box 516, 751 85, Uppsala, Sweden  
<sup>b</sup> Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, SE-141 77, Stockholm, Sweden

**ARTICLE INFO**      **ABSTRACT**

**Keywords:** Anorexia nervosa, Eating disorders, Overweight, Radical open dialectical behavior therapy, Single-case experimental design

**Background and objectives:** No treatment for adult anorexia nervosa (AN) has shown sufficient effectiveness or superiority to other treatments. Overweight has been suggested as a viable medication to target in the treatment of patients with AN. Radically open dialectical behavior therapy (RO DBT) is developed for disorders related to maladaptive overcontrol. Our objective was to evaluate the outcome of RO DBT for AN in a clinical outpatient setting.


**Methods:** Thirteen adult female patients with mild to moderate AN provided written consent and entered a multiple baseline single-case experimental design study. Median age at eating disorder (ED) onset was 15 years and the median duration of the ED was 13 years. Individual changes were assessed weekly during a baseline phase (A) of four to six weeks, and during the subsequent 40-week RO DBT phase (B). Additional assessments were conducted before and after treatment, and at a six-month follow-up. Primary outcome was ED psychopathology; secondary outcomes were psychosocial impairment, quality of life, social consequences, and adaptive control strategies.

**Results:** Eight patients (62%) completed treatment. All completers were in full remission after treatment, with BMI >18.5 kg/m<sup>2</sup> and ED psychopathology within one standard deviation of the community mean. Improvements occurred after introducing RO DBT, not during baseline.

**Limitation:** Participants were female with mild to moderate AN, limiting generalizability to severe AN or males.

**Conclusion:** The study provides preliminary support for using RO DBT in adult outpatients with AN and overweight. Further studies should replicate these findings.


16

 **Karolinska Institutet**


## RO-DBT for anorexia nervosa

Radical openness?  
 > Gå emot din vanliga tendens + mer villighet  
 > Inse vad du undviker + sök exponering  
 > Meta-perspektiv: Villighet att ha fel och korrigera sig  
 > Öppenhet och förändring, ej bara acceptans!  
 Passar anorexia nervosa  
 > Kraftig överkontroll  
 > Dikotomt, rigid tänkande, perfektionism, tvångsmässighet

17

 **Karolinska Institutet**

## Resultat



18

Karolinska Institutet

## Utfall

Primära utfall

- Alla som fullföljde hade en reliabel förändring och uppnådde full remission
- 6/8 var i full remission vid 6-månadersuppföljning
- 4/5 som föll bort hade uppnått partiell remission

19

Karolinska Institutet

## Kan man bli frisk efter 20 års sjukdom!

- Ja!
- Vissa lyckas tillfriskna bra trots långtids sjukdom
- Skilj mellan ätstörning och specifika personlighetsdrag i bedömning av residualsymptom
- Om inte bli frisk, kan vi hjälpa dem få högre livskvalitet:
  - Gemensam målsättning är A och O

20

Karolinska Institutet

## ACT kontra KBT

- Risk för undvikande (exponering för mat och ätande) vid ACT
  - Parling, T., Cernvall, M., Ramklint, M., Holmgren, S., & Ghaderi, A. (2016). A randomised trial of Acceptance and Commitment Therapy for Anorexia Nervosa after day-care treatment, including five-year follow-up. *BMC Psychiatry*, 16:272. DOI: 10.1186/s12888-016-0975-6.
- Svag evidens för ACT vid ätstörningar
  - Linardon et als meta-analys (2017):
    - "...none of the third-wave therapies meet established criteria for an empirically supported treatment for particular eating disorder subgroups.
- Tilltalande för patient och terapeut: dock risk för svag effekt

21

Karolinska Institutet

## Kärnkomponenten i KBT-E: Tappa inte dem i individualiseringen!

Regelbundet ätande (exponering)  
Stimulus kontroll (sluta kompensera, få in rutiner, skapa nya stimulusrelationer)  
Förstå funktionen av stort ätande (Funktionell analys) /insikt  
Beteendeaktivering (Alternativa beteenden)  
Meta-kognitiv medvetenhet  
Kroppsacceptans  
Balansering av självbild  
Vidmakthållande av resultat/förändringar

22

Karolinska Institutet

## Intuitivt ätande

- Intuitivt ätande har samband med mindre hetsätning, emotionellt ätande, kroppsmissnöje och återhållsamhet i ätande
- Det är relaterat till mer uppskattning av kroppen, acceptans, självmedkänsla och välbefinnande
- Kvinnor i mindre grad äter intuitivt än män
- Linardon, J., Tyka, T & Fuller-Tyszkiewicz, M (2021). *IJED*

23

Karolinska Institutet

## Acceptansmodell för intuitivt ätande

```

graph LR
    UA[Unconditional acceptance from others] --> BF[Body function]
    BA[Body acceptance by others] --> BF
    BF --> BA[Body appreciation]
    BA --> IE[Intuitive eating]
    IE --> UA
  
```

24

### Intolerans av osäkerhet

- Transdiagnostik process vid ångeststörningar
- Aktuellt vid ätstörningar
- Flera pågående projekt
- Oklar betydelse i behandling av ätstörningar

25

### KBT-E för svåra ätstörningar? Enstaka studier!

26

### Svår och ihållande AN

- Majoriteten verkar inte få specialiserad behandling (global bild)
- Extrem heterogenitet i behandlingar som ges
- **Duration av AN (kronicitet) tycks inte vara så avgörande för utfall. Folk tillfrisknar även efter 10-20 år av AN, åtminstone delvis!**
- Hög konsumtion av hälso- och sjukvård, trots att man inte får specialiserad vård

27

### Sen effekt av TMS vid svår AN?

- Dubbelblind studie av TMS vid AN
- 20 sessioner av hög frekvens av rTMS av DLPFC
- 34 patienter
- Modesta effekter vid avslutad behandling på vikt och ätstörning
- Vid 18-månadersuppföljning: 45.5% i behandlingsgruppen hade nått BMI>18.5 kontra 9% i falsk rTMS.
- Långsam effect av rTMS på placiticitet?

28

### Frostad et al (2021). Enhanced cognitive behaviour therapy (CBT-E) for severe and extreme anorexia nervosa in an outpatient... Journal of Eating Disorders, 9, 143.

21 patienter (Norge) med BMI<16 mellan 17 och 51 år  
11 patienter fullföljde inte behandlingen, men fick viss viktuppgång.  
Vid 1-årsuppföljning 14/21 (66.7%) hade ett BMI över 18.5.  
Inga svåra komplikationer under behandlingen!  
Se också: Frostad et al. Journal of Eating Disorders (2018) 6:12

29

### Della Grave et al (2014). Inpatient cognitive... Frontiers in Psychiatry, 5:14

Tonåringar 13-17 år med svår anorexi  
Ej lyckats med öppenvårdsbehandling eller instabila  
20 veckors intensive KBT-E (13 ineliggande, 7 på dagvård)  
26 av 27 (96%) fullföljde programmet  
Signifikant förbättring i viktstatus och ätstörningssymptom  
Resultat höll i sig vid 1-årsuppföljningen

Table 1 | Characteristics of the patients before treatment, after treatment, and at 6- and 12-month follow-up (intent-to-treat data set, n = 27).

	Before treatment	After treatment	6-month follow-up	12-month follow-up
Weight				
Body weight (kg)	38.5 (6.1)	49.7 (5.6) <sup>a</sup>	45.7 (7.0) <sup>a,b</sup>	48.1 (7.3) <sup>a</sup>
Body mass index centile	2.7 (4.2)	34.2 (15.7) <sup>a</sup>	27.3 (20.8) <sup>a,b</sup>	29.9 (20.1) <sup>a</sup>
Eating disorder psychopathology				
Overall severity (global EDE)	3.7 (1.3)	2.1 (1.2) <sup>a</sup>	2.1 (1.7) <sup>a</sup>	1.7 (1.3) <sup>a</sup>
Global EDE <1 SD above the community mean <sup>c</sup> , n (%)	2 (14)	10 (37.0)	14 (51.9)	14 (51.9)

30

REVIEW

## Effectiveness då: Funkar det i klinik? Ja 50 studier i meta-analys!

**Cognitive behavior therapy for adult eating disorders in routine clinical care: A systematic review and meta-analysis**

Lars-Göran Öst PhD<sup>1,2,3,4</sup> | Martin Brattmyr MSc<sup>1</sup> | Anna Finesse PhD<sup>5,6</sup> | Ata Ghaderi PhD<sup>7</sup> | Audun Havnen PhD<sup>8,9</sup> | Maria Hedman-Lageröf PhD<sup>7</sup> | Thomas Parling PhD<sup>10</sup> | Elisabeth Welch PhD<sup>11</sup> | Gao Jianme Wergeland MD, PhD<sup>12,13</sup>

**Abstract**  
**Objective:** Cognitive behavior therapy (CBT) is a recommended treatment for eating disorders (ED) in adults given its evidence, mainly based on efficacy studies. However, little is known about how CBT works in routine clinical care. The goal of the present meta-analysis is to investigate how CBT works for various ED when carried out in routine clinical settings.  
**Method:** OAI MEDLINE, Embase OVID, and PsycINFO were systematically searched for articles published until June 2023. The outcome of CBT, methodological quality, risk of bias (RoB), and moderators of treatment outcome were examined and benchmarked by meta-analytically comparing with efficacy studies for ED. Fifty studies comprising 1279 participants who received CBT were included.  
**Results:** Large within-group effect sizes (ES) were obtained for ED-psychoopathology at post-treatment (1.12), and follow-up (1.22), on average 19 months post-treatment. Attrition rate was 25.5% and RoB was considerable in the majority of studies. The benchmarking analysis showed that effectiveness studies had very similar ESs as efficacy studies (1.20 at post-treatment and 1.28 at follow-up).  
**Conclusion:** CBT for ED is an effective treatment when delivered in routine clinical care, with ESs comparable to those found in efficacy studies. However, the evidence needs to be interpreted with caution due to the RoB in a high proportion of studies.  
**Public significance:** Eating disorders are common in the population and often lead to multiple negative consequences. CBT has been found effective for ED and is recommended in clinical guidelines. Since these recommendations are primarily based on university studies we wanted to investigate how CBT performs in routine clinical care. Our meta-analysis found that CBT worked as well in routine care as in university setting studies.

© Ala Chahed

31

**TABLE 6** Effect sizes on ED-psychoopathology measures and BMI for effectiveness and efficacy studies at post-assessment and follow-up assessment.

Time point	Disorder	Study type	k	g	95% CI	z-value	95% PI	Q <sup>2</sup>	p-value	
Post	All disorders	Effectiveness	59	1.12	.98–1.25	16.21 <sup>b</sup>	.15–2.09	.72	.40	
		Efficacy	60	1.20	1.06–1.34	17.32 <sup>b</sup>	.23–2.17			
		AN	Effectiveness	10	1.46	1.14–1.78	8.89 <sup>b</sup>	.40–2.52	5.71	.02
			Efficacy	7	.85	.48–1.23	4.44 <sup>b</sup>	–.24 to 1.94		
		BN	Effectiveness	23	.98	.76–1.20	8.71 <sup>b</sup>	–.02–1.99	4.33	.04
			Efficacy	24	1.31	1.09–1.54	11.62 <sup>b</sup>	.30–2.32		
	BED	Effectiveness	11	1.11	.80–1.43	6.91 <sup>b</sup>	.05–2.18	.07	.79	
		Efficacy	19	1.06	.82–1.30	8.56 <sup>b</sup>	.01–2.10			
	Mix	Effectiveness	12	1.13	.88–1.39	8.66 <sup>b</sup>	.34–2.04	2.89	.09	
		Efficacy	10	1.47	1.18–1.76	8.91 <sup>b</sup>	.56–2.39			
	Follow-up	All disorders	Effectiveness	31	1.22	1.04–1.41	12.98 <sup>b</sup>	.21–2.23	.15	.70
			Efficacy	49	1.28	1.13–1.43	16.74 <sup>b</sup>	.31–2.26		
AN			Effectiveness	6	1.59	1.10–2.09	6.32 <sup>b</sup>	.20–2.99	2.04	.16
			Efficacy	6	1.09	.60–1.58	4.38 <sup>b</sup>	–.31 to 2.48		
BN			Effectiveness	10	1.12	.77–1.47	6.28 <sup>b</sup>	.01–2.24	1.08	.30
			Efficacy	21	1.32	1.10–1.55	11.64 <sup>b</sup>	.35–2.28		
BED		Effectiveness	9	.96	.64–1.29	5.80 <sup>b</sup>	–.06 to 1.99	.70	.41	
		Efficacy	15	1.14	.88–1.40	8.66 <sup>b</sup>	.14–2.14			
Mix		Effectiveness	6	1.46	1.02–1.90	6.54 <sup>b</sup>	.26–2.66	.43	.52	
		Efficacy	7	1.66	1.26–2.06	8.08 <sup>b</sup>	.49–2.85			
Post		BMI in AN	Effectiveness	11	2.30	1.87–2.73	10.43 <sup>b</sup>	.83–3.77	5.02	.03
			Efficacy	7	1.52	.99–2.05	5.66 <sup>b</sup>	.01–3.03		
Follow-up	BMI in AN	Effectiveness	6	1.86	1.39–2.34	7.67 <sup>b</sup>	.59–3.13	1.51	.22	
		Efficacy	6	1.45	.99–1.91	6.20 <sup>b</sup>	.10–2.71			

32

**Karolinska Institutet**

## Skillnader mellan efficacy och effectiveness

**TABLE 5** Some background and treatment data (M and SD) for effectiveness and efficacy studies.

Type of study	k	Age (years)	% females	% severity	% comorbid	% medicated	Tx hours	% attrition
Effectiveness	62	29.0 (5.6)	95.1 (5.2)	61.1 (10.5)	47.1 (16.3)	24.3 (20.6)	40.7 (42.7)	25.1 (13.0)
Efficacy	70	32.1 (8.5)	94.8 (6.4)	54.5 (10.3)	42.4 (16.2)	13.8 (17.5)	20.2 (18.0)	21.6 (12.3)
p-value		.02	.76	<.001*	.29	.04	<.001*	.12

© Ala Chahed

33

**Karolinska Institutet**

## Många andra linjer i forskning...

- Mindfulness & Mindful eating
- Neuroleptika vid AN
- Emotionsreglering
- Diagnostisk (t.ex. Ortorexi...)
- Prevention och riskfaktorer
- Anknnytning, mentalisering...
- EMA (Ecological Momentary Assessments)
- Genetik
- Hjärnabbildning

34

**Karolinska Institutet**

## Sammanfattningsvis

Hygglig evidens för effekt av KBT-E  
 Inte mer än 30-70% tillfrisknar  
 Det finns utrymme för förbättring av CBT-E!

© Ala Chahed

35